Skip to content
To the full analysis

IRadimed stock: balance sheet and debt

IRMD
$85.23Closing price of 12 Nov 2026MEQIRI Score 75 out of 100

IRadimed has a debt to equity ratio of 0 and an interest coverage of over 100x.

Daily figure as of 13 Nov 2026

Debt / Equity
0
Interest coverage
> 100x
Current ratio
7.98
Cash & equivalents
$51.16M
Total assets
$108.78M
Equity ratio
87%
Goodwill and intangible assets
$3.38M
not split out
Net debt
−$51.16M
More cash than debt

Total assets and equity ratio

How large the balance sheet of IRadimed Corporation is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2012$5.55M$276.03Knot split out58.0%−$1.43M
2013$6.99M$267.02Knot split out77.6%−$2.7M
2014$23.31M$250.84Knot split out89.6%−$17.37M
2015$35.24M$175.51Knot split out90.6%−$26.97M
2016$37.19M$918.71Knot split out85.7%−$25.68M
2017$39.01M$885.5Knot split out84.4%−$26.34M
2018$48.44M$832.52Knot split out86.6%−$34.38M
2019$66.73M$860.09Knot split out83.2%−$43.29M
2020$71.07M$960.89Knot split out86.4%−$49.26M
2021$82.88M$1.12Mnot split out87.1%−$60.02M
2022$85.51M$2.07Mnot split out86.2%−$55.76M
2023$92.16M$2.52Mnot split out77.5%−$47.72M
2024$98.33M$3.1Mnot split out88.3%−$52.08M
2025$108.78M$3.38Mnot split out87.0%−$51.16M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2012$1.95M$3.22M$519.73K0.16
2013$2.71M$5.42M$6.33K0
2014$17.37M$20.89M$00
2015$26.97M$31.93M$00
2016$25.68M$31.89M$00
2017$26.34M$32.93M$00
2018$34.38M$41.95M$00
2019$46.25M$55.52M$2.96M0.05
2020$51.98M$61.38M$2.72M0.04
2021$62.5M$72.17M$2.48M0.03
2022$57.96M$73.67M$2.21M0.03
2023$49.76M$71.42M$2.04M0.03
2024$52.23M$86.82M$154.69K0
2025$51.16M$94.62M$00

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Strong, published since 7 Nov 2026 (in the score history since 31 May 2024)
  • Valuation signal Fairly valued since 12 Nov 2026, previously Overvalued
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy